Abstract
目的: 探讨表皮生长因子受体(EGFR)基因突变与ROS1基因融合共存型(简称“ER双突变”)肺癌患者的临床病理学特征及治疗与预后。 方法: 回顾性分析ER双突变肺癌患者的临床病理特征,并对患者进行随访,探讨其临床治疗及预后。 结果: (1)1 586例非小细胞肺癌患者的EGFR突变率为51.5%(816/1 586),ROS1融合突变率为2.4%(38/1 586),ROS1融合与患者的年龄、吸烟史、病灶部位有关。(2)38例ROS1融合非小细胞肺癌患者中,4例为ER双突变,占比10.5%(4/38)。4例均为女性、肺腺癌患者,中位年龄62岁,均无吸烟史,临床分期Ⅰ期、Ⅱ期、Ⅲ期、Ⅳ期各1例。EGFR以第19号外显子缺失突变多见,ROS1融合以R2型多见。(3)4例ER双突变患者中位随访8.5个月,其中Ⅰ期患者右上肺叶切除术后随访22个月疾病无进展;Ⅱ期患者左下肺叶切除术后辅助化疗,随访6个月疾病无进展;Ⅲ期患者右中肺癌根治术后随访6个月疾病无进展;Ⅳ期患者伴肺、肝、骨转移,第一代EGFR-酪氨酸激酶抑制剂(TKI)治疗8个月后出现脑转移,血液EGFR检测示T790M突变,二线接受第三代EGFR-TKI治疗,3个月后复查脑转移灶略缩小,疾病稳定。 结论: ER双突变肺癌在临床上较少见,多见于女性、不吸烟、肺腺癌患者,其可能从EGFR-TKI靶向治疗中获益。非小细胞肺癌患者在靶向治疗之前进行驱动基因联合检测,有助于靶向药物的选择以及预后判断。.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Zhonghua bing li xue za zhi = Chinese journal of pathology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.